Abstract. Background/Aim: Cortactin (CTTN) Cutaneous squamous cell carcinoma (CSCC) is the second most common keratinocyte carcinoma (1). Although CSCC has a relatively low recurrence and metastasis rate (2), its incidence is rapidly increasing (3). As the molecular pathogenesis of CSCC is heavily influenced by UV radiation-induced mutagenesis, investigation into the molecular basis of CSCC can provide more reliable diagnostic biomarkers, as well as therapeutic targets.
Cutaneous squamous cell carcinoma (CSCC) is the second most common keratinocyte carcinoma (1) . Although CSCC has a relatively low recurrence and metastasis rate (2), its incidence is rapidly increasing (3) . As the molecular pathogenesis of CSCC is heavily influenced by UV radiation-induced mutagenesis, investigation into the molecular basis of CSCC can provide more reliable diagnostic biomarkers, as well as therapeutic targets.
The Src family tyrosine kinases are known to be involved in integrin-mediated biological processes including cell proliferation, actin organization, and cell migration (4) (5) (6) (7) (8) (9) . Some investigators have demonstrated that Src is frequently hyperactivated in various types of cancers, particularly in metastatic lesions (6, 10, 11) . The critical roles of Src family kinases are thought to be largely dependent on their substrates, and cortactin is known as a direct substrate of cellular Src kinase (12) .
As an actin binding protein, cortactin (CTTN) is encoded by the CTTN gene, located at chromosome 11q13 and enriched in the lamellipodia and membrane ruffles of cells; it regulates actin dynamics and is known to be associated with cell motility in vitro (13, 14) . Overexpression and amplification of CTTN are frequently detected in various types of cancers and are considered a promising indicator of poor prognosis (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) . More recently, many researchers have analyzed post-translational modifications of CTTN (16, 17, 27) . Moreover, studies have demonstrated that tyrosine phosphorylation of CTTN is mediated by various tyrosine kinases such as Src (28, 29) .
Src can phosphorylate CTTN at the sites of three tyrosine residues Tyr421, Tyr466, and Tyr482 in vitro (30) . Srcmediated CTTN phosphorylation has been reported to be involved in the integrin-induced cell spreading and adhesion process (31) . Compared to CTTN, which is colocalized in lamellipodia with Src and actin, tyrosine phosphorylated CTTN (p-CTTN) is located at focal adhesions, especially at the ends of F-actin stress fibers, all three tyrosine residues Tyr421, Tyr466, and Tyr482 of CTTN are being phosphorylated upon focal adhesion (32, 33) . Phosphorylation of Tyr421, Tyr466, and Tyr482 of CTTN has frequently been observed in vitro in many types of cells including cancer cells, and is a critical factor in cell migration (29, 30, 34, 35) . In gastric cancer cell lines, decreased cell motility induced by CTTN knockdown was restored by wild-type CTTN overexpression, but not by CTTN mutated in tyrosine residues such as Tyr421, Tyr466, and Tyr482 (36) . Similar results have also been reported in breast cancer cell lines (37) . Moreover, after transfecting mutant CTTN (Tyr 421/466/482), endothelial cells presented decreased cell motility in vitro (38) . In spite of several in vitro studies demonstrating the critical role of p-CTTN in the motility of several cell types, little is known regarding the clinicopathological implications of p-CTTN in cancer patients.
In this study, we investigated the influence of CTTN expression on the biological behavior of CSCC cell lines, for the first time, as well as the clinicopathological significance of both CTTN and p-CTTN in a cohort of CSCC patients.
Materials and Methods
Clinical materials. In total, 10 normal skin and 38 CSCC tissue specimens were included in this study. All specimens were obtained from the Department of Pathology, Yonsei University Health System in Seoul, Korea. The clinicopathological characteristics of the patients are summarized in Table I . This study was approved by the Institutional Review Board for Bioethics of Yonsei University Health System, Severance Hospital (IRB 2018-0874-001).
Immunochemical staining. For immunohistochemistry, the tissue sections were deparaffinized with xylene and hydrated using a graded ethanol. After antigen retrieval and blocking of endogenous peroxidase activity, the sections were incubated with primary antibody at RT for 1 h. Each group of cells was seeded in a chamber slide (Thermo Fisher Scientific, Waltham, MA, USA) at a density of 2×10 4 . After 24 h of culture, the cells were fixed with 95% ethanol for 30 min at RT, and then incubated with primary antibody at RT for 1 h. Cortactin (Abcam, Cambridge, MA, USA), pTyr421-CTTN (LifeSpan BioSciences, Seattle, WA, USA) and p Try466-CTTN (LifeSpan BioSciences) were used in this study, and REAL EnVision HRP Rabbit/Mouse Detection System (Dako, Santa Clara, CA, USA) was used as secondary antibody. Visualization was performed using the chromogen 3,3'-diaminobenzidine and counterstaining was performed with hematoxylin. Rabbit IgG (DakoCytomation Denmark A/S, Glostrup, Denmark) was used as a negative control.
As described in a previous study, the weighted histoscore method was used to score each protein expression according to staining intensity and the percentage of positive cells (39) . The tumour cell intensity was scored as 0 (negative), 1 (light brown), 2 (brown), and 3 (dark brown). The histoscore was calculated as follows: Total score=(0× percentage of negative cells) + (1× percentage of lightbrown cells) + (2× percentage of brown cells) + (3 × percentage of dark-brown cells). Based on the total histoscore, the samples were further divided into two expression groups, low (histoscores 0 through 100) and high (histoscores 101 through 300).
Cell lines and culture. Human CSCC cells (HSC-1 and HSC-5) were obtained from the Japanese Collection of Research Bioresources (Osaka, Japan) for use in this study. These cell lines were cultured in Roswell Park Memorial Institute 1640 medium (Nissui Pharmaceutical Co., Ltd., Tokyo, Japan) supplemented with 10% foetal bovine serum (Invitrogen, Carlsbad, CA, USA), 100 U/ml penicillin, and 0.1 mg/ml streptomycin-amphotericin B (Lonza, Basel, Switzerland), at 37˚C under a humidified 5% CO 2 atmosphere. CTTN knockdown in these cells was performed by short-interfering RNA (siRNA) transfection (siCTTN; invitrogen) using Lipofectamin 2000 (Invitrogen) according to the manufacturer's protocol. A scrambled (Scr)-siRNA (Bioneer, Korea) was used as negative control. Knockdown efficiency was determined by reversetranscription real-time quantitative polymerase chain reaction (RTqPCR) and immunochemical staining.
RT-qPCR.
Total RNA was isolated from HSC-1 and HSC-5 cells after transfection with CTTN-siRNA or Scr-siRNA using TRIzol Reagent (Invitrogen) according to the manufacturer's protocol. CTTN, marker of proliferation Ki-67 (MKI67), and proliferating cell nuclear antigen (PCNA) mRNA expression was investigated following complementary DNA synthesis by qPCR analysis using 2× SYBR Premix Ex Taq II (Tli RnaseH Plus) (RR82LR; Takara, Ann Arbor, MI, USA) on an Applied Biosystems (Foster City, CA, USA) instrument. The following primers were used: MKI67 forward: 5'-CCCCCACCAGAACTAACAGA-3' and reverse: 5'-ACTTTGAT GCCCTCATCACC-3'; PCNA forward: 5'-GAAGCACCAAACCA GGAGAA-3' and reverse: 5'-TCACTCCGTCTTTTGCACAG-3'; β-actin forward: 5'-ATAGCACAGCCTGGATAGCAACGTAC-3' and reverse: 5'-CACCTTCTACAATGAGCTGCGTGTG-3'. The relative expression of each gene was normalized with β-actin mRNA expression.
The influences of CTTN knockdown on the biological behaviour of the CSCC cells.
To investigate the influence of CTTN expression on the biological behaviour of the cells, trypan blue assay, migration assay, and matrigel invasion assay were performed in HSC-1 and HSC-5 cells after transfection with CTTN-siRNA or Scr-siRNA. For trypan blue assay, those cells were seeded in a 6-well plate at a density of 1×10 4 and counted each day for 3 days after trypan blue staining. For wound-healing assay, each group of cells were seeded in a 24-well plate at a density of 3×10 4 . At 90% confluency a scratch wound was made, whose relative closure was investigated after 24 h. For matrigel invasion assay, each group of cells was seeded in a Matrigel-(BD Biosciences, San Jose, CA, USA) coated upper chamber of a transwell (BD Biosciences, Bedford, MA, USA) at a density of 5×10 4 with culture medium containing 1% FBS. Culture medium containing 10% FBS was added in the bottom chamber. After 30 h of culture, invading cells were stained with 0.25% crystal violet and counted under the microscope.
Statistical analysis. The association between CTTN protein expression and clinicopathological variables of CSCC patients was analyzed with Fisher's exact test. Mann-Whitney U-test was used to examine the influences of CTTN knockdown on the biological behavior of the CSCC cells. Differences were considered to be statistically significant when p<0.05. in vivo 33: 393-400 (2019) 
Results

CTTN, pTyr421-CTTN, and pTry466-CTTN expression in normal skin and CSCC tissue samples.
Representative expression patterns of CTTN, pTyr421-CTTN, and pTry466-CTTN in the tissue samples are shown in Figure 1 . Cytoplasmic expression of CTTN, pTyr421-CTTN, and pTry466-CTTN was frequently found in normal epithelial cells and cancer cells in tissue specimens. No significant difference was found between normal skin and CSCC samples in CTTN protein expression. High-CTTN expression was found in 7 (70%) and 26 (68.4%) of the normal skin and CSCC tissue samples, respectively (Figure 2A ). In contrast, the frequency of both high-pTyr421-CTTN and high-pTry466-CTTN expression was significantly increased in CSCC tissues relative to normal skin tissue samples (p=0.003, and p=0.008, respectively). High-pTyr421-CTTN and high-pTry466-CTTN expression was found in 21 (47.4%) and 18 (55.3%) CSCC tissue samples, respectively. However, no normal skin tissue samples exhibited high immunoreactivity for either pTyr421-CTTN or high-pTyr466-CTTN (Figure 2A) .
The clinicopathological significance of the expression of all three proteins in the 38 patients with CSCC was further investigated. None of the baseline clinicopathological parameters, including age, gender, site, tumor size, and differentiation of involvement, were significantly associated with tissue CTTN, pTyr421-CTTN, or pTyr466-CTTN expression in patients with CSCC (Table II) . Meanwhile, Kaplan-Meier analysis showed that both pTyr421-CTTN and pTry466-CTTN expression were significantly correlated with recurrence-free survival of patients with CSCC. As a result, patients with high expression of pTyr421-CTTN (median survival duration of 29 months in the low expression group versus 13.7 months in the high expression group; p=0.014) or pTry466-CTTN (median survival duration of 47.4 months in low expression group versus 12.0 months in high expression group; p=0.006) exhibited poor recurrence-free survival rates ( Figure 2B ). 
Efficient CTTN knockdown by siRNA transfection of human CSCC cancer cell lines. CTTN knockdown in CSCC cell
CTTN knockdown attenuated CSCC cell migration and invasion.
The effect of CTTN on CSCC cell migration was investigated using a wound-healing assay. Compared to the related ScrsiRNA control, transfection of CTTN-siRNA significantly reduced the migration ability of both HSC-1 and HSC-5 cells as measured at 24 h after scratch wounding ( Figure 3C ). In addition, the influence of CTTN on the invasion ability of CSCC cells was investigated by a matrigel invasion assay. The number of CTTN-siRNA transfected HSC-1 and HSC-5 cells having traversed the membrane was found to be significantly decreased (both p<0.001) compared to the Scr-control ( Figure 3C ).
Discussion
Despite ongoing efforts to identify the role of CTTN in tumorigenesis of various types of cancers, it has not been investigated in CSCC. In this study, the influence of CTTN knockdown on the proliferation, migration, and invasion abilities of CSCC cell lines was investigated. Similar to other cancers, CTTN knockdown significantly attenuated both the migration and invasion ability of CSCC cells (21, 22) . Moreover, the proliferation ability of CSCC cell lines was also decreased after CTTN knockdown. These data suggest that cortactin may play a critical role in CSCC progression. Clinicopathological implications of CTTN overexpression have been investigated in various types of cancers, such as head and neck, colorectal, gastric cancers, renal cell carcinoma, breast cancers, and osteosarcoma. Studies have demonstrated that CTTN overexpression is significantly associated with various indicators of poor prognosis including higher T stage, lymph node metastasis, increased recurrence rates and decreased overall survival in cancer patients (18-23, 40, 41) . In the present study, a strong CTTN expression was found in CSCC tissue samples, but strong immunoreactivity to CTTN was also frequently observed in normal skin tissue samples, and the difference was not significant. Moreover, in our cohort of CSCC, no significant association was found between CTTN expression and clinicopathological parameters of patients. Some previous studies have reported the absence of CTTN expression in benign tissues, in contrast to the results of this study (22, 25) , while other studies have also found CTTN expression in normal tissues (18) (19) (20) investigators have shown increased CTTN expression in benign tumor tissues compared to in malignant ones (42) . The CTTN expression levels in tissues may largely depend on the tissue type in question. Recent findings indicate that Src-mediated p-CTTN overexpression is more important for the migration ability of cells than CTTN overexpression, there being no demonstrably significant influence on migration ability of cells after transfection of mutant type CTTN (Try421/466/482 mutation) (36, 38) . Moreover, decreased cell migration ability has been observed after blocking tyrosine phosphorylation of CTTN (33) . Increased cell motility plays a critical role in various cell pathological processes including metastasis and recurrence. Some investigators have noticed overexpression of CTTN in malignant tumors, and an association between CTTN phosphorylation and increased cell motility, as well as metastasis (6, 15) . In this study, p-CTTN expression was detected using the phospho-specific antibodies anti-pTyr421-and anti-pTyr466-CTTN, and the results showed that the expression of both was significantly increased in CSCC tissue samples relative to normal skin tissues. Moreover, a significant association was found between CTTN phosphorylation and recurrence-free survival in CSCC patients. These findings indicate a crucial role of p-CTTN expression in CSCC progression.
The molecular mechanisms related to p-CTTN functions remain largely unknown. As a F-actin related protein, CTTN is known to cross-link F-actin into meshwork in vitro. Tyrosine phosphorylation is known to inhibit the ability of CTTN to cross-link F-actin, but it remains controversial whether it affects the ability of CTTN to crosslink actin filaments (43) (44) (45) . Investigators have shown that CTTN tyrosine phosphorylation controls cell functions by establishing binding sites for effectors such as Nck and Src family kinase (46) . Further study is needed to clarify the precise mechanism of p-CTTN function in CSCC.
In summary, CTTN knockdown strongly influenced the biological behavior of CSCC cell lines. Moreover, p-CTTN expression was significantly increased in CSCC tissues relative to normal skin samples, as well as being significantly associated with recurrence-free survival of CSCC patients. CTTN phosphorylation may thus be involved in CSCC pathogenesis. These findings also provide evidence that p-CTTN may serve as a predictive biomarker, as well as therapeutic target in CSCC patients. A larger patient cohort is needed to investigate the clinicopathological implications of both cortactin and p-CTTN for CSCC pathogenesis.
